Literature DB >> 26476331

Phenotypic, metabolic, and molecular genetic characterization of six patients with congenital adrenal hyperplasia caused by novel mutations in the CYP11B1 gene.

Huy-Hoang Nguyen1, Antje Eiden-Plach2, Frank Hannemann2, Ewa M Malunowicz3, Michaela F Hartmann4, Stefan A Wudy4, Rita Bernhardt5.   

Abstract

Congenital adrenal hyperplasia (CAH) is an autosomal recessive inherited disorder of steroidogenesis. Steroid 11β-hydroxylase deficiency (11β-OHD) due to mutations in the CYP11B1 gene is the second most common form of CAH. In this study, 6 patients suffering from CAH were diagnosed with 11β-OHD using urinary GC-MS steroid metabolomics analysis. The molecular basis of the disorder was investigated by molecular genetic analysis of the CYP11B1 gene, functional characterization of splicing and missense mutations, and analysis of the missense mutations in a computer model of CYP11B1. All patients presented with abnormal clinical signs of hyperandrogenism. Their urinary steroid metabolomes were characterized by excessive excretion rates of metabolites of 11-deoxycortisol as well as metabolites of 11-deoxycorticosterone, and allowed definite diagnosis. Patient 1 carries compound heterozygous mutations consisting of a novel nonsense mutation p.Q102X (c.304C>T) in exon 2 and the known missense mutation p.T318R (c.953C>G) in exon 5. Two siblings (patient 2 and 3) were compound heterozygous carriers of a known splicing mutation c.1200+1G>A in intron 7 and a known missense mutation p.R448H (c.1343G>A) in exon 8. Minigene experiments demonstrated that the c.1200+1G>A mutation caused abnormal pre-mRNA splicing (intron retention). Two further siblings (patient 4 and 5) were compound heterozygous carriers of a novel missense mutation p.R332G (c.994C>G) in exon 6 and the known missense mutation p.R448H (c.1343G>A) in exon 8. A CYP11B1 activity study in COS-1 cells showed that only 11% of the enzyme activity remained in the variant p.R332G. Patient 6 carried a so far not described homozygous deletion g.2470_5320del of 2850 bp corresponding to a loss of the CYP11B1 exons 3-8. The breakpoints of the deletion are embedded into two typical 6 base pair repeats (GCTTCT) upstream and downstream of the gene. Experiments analyzing the influence of mutations on splicing and on enzyme function were applied as complementary procedures to genotyping and provided a rational basis for understanding the clinical phenotype of CAH.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  11β-hydroxylase; CYP11B1; CYP11B1 mutant; Congenital adrenal hyperplasia; Steroid hormone

Mesh:

Substances:

Year:  2015        PMID: 26476331     DOI: 10.1016/j.jsbmb.2015.10.011

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  8 in total

1.  Detection of Small CYP11B1 Deletions and One Founder Chimeric CYP11B2/CYP11B1 Gene in 11β-Hydroxylase Deficiency.

Authors:  Hua Xie; Hui Yin; Xue Ye; Ying Liu; Na Liu; Yu Zhang; Xiaoli Chen; Xiaobo Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-24       Impact factor: 6.055

Review 2.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 3.  Steroid hormone analysis in diagnosis and treatment of DSD: position paper of EU COST Action BM 1303 'DSDnet'.

Authors:  A Kulle; N Krone; P M Holterhus; G Schuler; R F Greaves; A Juul; Y B de Rijke; M F Hartmann; A Saba; O Hiort; S A Wudy
Journal:  Eur J Endocrinol       Date:  2017-02-10       Impact factor: 6.664

4.  Utility of a Commercially Available Blood Steroid Profile in Endocrine Practice.

Authors:  Vijaya Sarathi; Sridevi Atluri; T V S Pradeep; Sindhu S Rallapalli; Chintala V Rakesh; Tirupati Sunanda; K Dileep Kumar
Journal:  Indian J Endocrinol Metab       Date:  2019 Jan-Feb

Review 5.  Vitamin D: Current Challenges between the Laboratory and Clinical Practice.

Authors:  Ludmila Máčová; Marie Bičíková
Journal:  Nutrients       Date:  2021-05-21       Impact factor: 5.717

6.  Splicing analysis of CYP11B1 mutation in a family affected with 11β-hydroxylase deficiency: case report.

Authors:  Pattaranatcha Charnwichai; Patra Yeetong; Kanya Suphapeetiporn; Vichit Supornsilchai; Taninee Sahakitrungruang; Vorasuk Shotelersuk
Journal:  BMC Endocr Disord       Date:  2016-06-17       Impact factor: 2.763

7.  CDHR1 mutations in retinal dystrophies.

Authors:  Katarina Stingl; Anja K Mayer; Pablo Llavona; Lejla Mulahasanovic; Günther Rudolph; Samuel G Jacobson; Eberhart Zrenner; Susanne Kohl; Bernd Wissinger; Nicole Weisschuh
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

Review 8.  Non-classical 11β-hydroxylase deficiency caused by compound heterozygous mutations: a case study and literature review.

Authors:  Dongdong Wang; Jiahui Wang; Tong Tong; Qing Yang
Journal:  J Ovarian Res       Date:  2018-09-17       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.